Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to become the first rival to Bristol-Myers Squibb's fast-growing Camzyos for ...
Each of these demos is self-contained and can be run either locally or using a cloud context. They are all configured using two steps.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback